CanProTarget
A residue-resolved prioritization platform for covalent cancer drug discovery. CanProTarget integrates cancer gene dependencies, small-molecule covalent ligand engagement measured by chemoproteomics, and base-editing evidence for individual cysteines, keeping each layer at the resolution it is measured at.